BofA analyst Tazeen Ahmad raised the firm’s price target on Apellis to $43 from $40 and keeps a Neutral rating on the shares after Apellis provided an update highlighting that the rate of ORV remains low with 8 confirmed cases so far and noting that over 26,000 vial have been shipped in Q3. While “encouraged” by signs of continued demand for Syfovre and continued low rates of ORV months after the initial reports, the firm says it continues to look for more clarity on launch dynamics.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on APLS:
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
- Apellis price target raised to $54 from $45 at Citi
- Apellis price target raised to $65 from $60 at Stifel
- Wedbush keeps Neutral rating on Apellis following corporate restructuring news